Compare ATI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | ARWR |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.6B |
| IPO Year | N/A | 1993 |
| Metric | ATI | ARWR |
|---|---|---|
| Price | $122.45 | $64.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $111.57 | $72.70 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 02-03-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 3.10 | N/A |
| Revenue | ★ $4,583,000,000.00 | $829,448,000.00 |
| Revenue This Year | $6.39 | N/A |
| Revenue Next Year | $8.30 | N/A |
| P/E Ratio | $38.23 | ★ N/A |
| Revenue Growth | 7.75 | ★ 23258.15 |
| 52 Week Low | $39.23 | $9.57 |
| 52 Week High | $123.96 | $76.76 |
| Indicator | ATI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 74.42 | 52.00 |
| Support Level | $115.80 | $63.00 |
| Resistance Level | $122.57 | $69.42 |
| Average True Range (ATR) | 3.27 | 3.58 |
| MACD | 0.08 | -1.34 |
| Stochastic Oscillator | 82.43 | 26.64 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.